222 related articles for article (PubMed ID: 26554652)
1. Complications of hyperglycaemia with PI3K-AKT-mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials.
Geuna E; Roda D; Rafii S; Jimenez B; Capelan M; Rihawi K; Montemurro F; Yap TA; Kaye SB; De Bono JS; Molife LR; Banerji U
Br J Cancer; 2015 Dec; 113(11):1541-7. PubMed ID: 26554652
[TBL] [Abstract][Full Text] [Related]
2. Higher Risk of Infections with PI3K-AKT-mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials.
Rafii S; Roda D; Geuna E; Jimenez B; Rihawi K; Capelan M; Yap TA; Molife LR; Kaye SB; de Bono JS; Banerji U
Clin Cancer Res; 2015 Apr; 21(8):1869-76. PubMed ID: 25649020
[TBL] [Abstract][Full Text] [Related]
3. Hyperglycemia and Phosphatidylinositol 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) Inhibitors in Phase I Trials: Incidence, Predictive Factors, and Management.
Khan KH; Wong M; Rihawi K; Bodla S; Morganstein D; Banerji U; Molife LR
Oncologist; 2016 Jul; 21(7):855-60. PubMed ID: 27151652
[TBL] [Abstract][Full Text] [Related]
4. Impact of patient ethnicity on the metabolic and immunologic effects of PI3K-mTOR pathway inhibition in patients with solid tumor malignancies.
Aggarwal R; Grabowsky J; Strait N; Cockerill A; Munster P
Cancer Chemother Pharmacol; 2014 Aug; 74(2):359-65. PubMed ID: 24934865
[TBL] [Abstract][Full Text] [Related]
5. The effectiveness of monotherapy with PI3K/AKT/mTOR pathway inhibitors in ovarian cancer: A meta-analysis.
van der Ploeg P; Uittenboogaard A; Thijs AMJ; Westgeest HM; Boere IA; Lambrechts S; van de Stolpe A; Bekkers RLM; Piek JMJ
Gynecol Oncol; 2021 Nov; 163(2):433-444. PubMed ID: 34253390
[TBL] [Abstract][Full Text] [Related]
6. Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway.
Busaidy NL; Farooki A; Dowlati A; Perentesis JP; Dancey JE; Doyle LA; Brell JM; Siu LL
J Clin Oncol; 2012 Aug; 30(23):2919-28. PubMed ID: 22778315
[TBL] [Abstract][Full Text] [Related]
7. Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations.
Ganesan P; Janku F; Naing A; Hong DS; Tsimberidou AM; Falchook GS; Wheler JJ; Piha-Paul SA; Fu S; Stepanek VM; Lee JJ; Luthra R; Overman MJ; Kopetz ES; Wolff RA; Kurzrock R
Mol Cancer Ther; 2013 Dec; 12(12):2857-63. PubMed ID: 24092809
[TBL] [Abstract][Full Text] [Related]
8. PIK3CA mutations in advanced cancers: characteristics and outcomes.
Janku F; Wheler JJ; Naing A; Stepanek VM; Falchook GS; Fu S; Garrido-Laguna I; Tsimberidou AM; Piha-Paul SA; Moulder SL; Lee JJ; Luthra R; Hong DS; Kurzrock R
Oncotarget; 2012 Dec; 3(12):1566-75. PubMed ID: 23248156
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of PI3K/AKT/mTOR signaling pathway promotes autophagy of articular chondrocytes and attenuates inflammatory response in rats with osteoarthritis.
Xue JF; Shi ZM; Zou J; Li XL
Biomed Pharmacother; 2017 May; 89():1252-1261. PubMed ID: 28320092
[TBL] [Abstract][Full Text] [Related]
10. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.
Janku F; Wheler JJ; Naing A; Falchook GS; Hong DS; Stepanek VM; Fu S; Piha-Paul SA; Lee JJ; Luthra R; Tsimberidou AM; Kurzrock R
Cancer Res; 2013 Jan; 73(1):276-84. PubMed ID: 23066039
[TBL] [Abstract][Full Text] [Related]
11. Targeting the PI3K/AKT/mTOR pathway: biomarkers of success and tribulation.
Owonikoko TK; Khuri FR
Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714559
[TBL] [Abstract][Full Text] [Related]
12. Development of PI3K inhibitors: lessons learned from early clinical trials.
Rodon J; Dienstmann R; Serra V; Tabernero J
Nat Rev Clin Oncol; 2013 Mar; 10(3):143-53. PubMed ID: 23400000
[TBL] [Abstract][Full Text] [Related]
13. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway.
Burris HA
Cancer Chemother Pharmacol; 2013 Apr; 71(4):829-42. PubMed ID: 23377372
[TBL] [Abstract][Full Text] [Related]
14. Molecular basis for class side effects associated with PI3K/AKT/mTOR pathway inhibitors.
Zhang Y; Yan H; Xu Z; Yang B; Luo P; He Q
Expert Opin Drug Metab Toxicol; 2019 Sep; 15(9):767-774. PubMed ID: 31478386
[No Abstract] [Full Text] [Related]
15. PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside.
Alzahrani AS
Semin Cancer Biol; 2019 Dec; 59():125-132. PubMed ID: 31323288
[TBL] [Abstract][Full Text] [Related]
16. Characterization, management, and risk factors of hyperglycemia during PI3K or AKT inhibitor treatment.
Liu D; Weintraub MA; Garcia C; Goncalves MD; Sisk AE; Casas A; Harding JJ; Harnicar S; Drilon A; Jhaveri K; Flory JH
Cancer Med; 2022 Apr; 11(8):1796-1804. PubMed ID: 35212193
[TBL] [Abstract][Full Text] [Related]
17. Targeting the PI3-kinase/Akt/mTOR signaling pathway.
Hassan B; Akcakanat A; Holder AM; Meric-Bernstam F
Surg Oncol Clin N Am; 2013 Oct; 22(4):641-64. PubMed ID: 24012393
[TBL] [Abstract][Full Text] [Related]
18. Rebound pathway overactivation by cancer cells following discontinuation of PI3K or mTOR inhibition promotes cancer cell growth.
Faes S; Santoro T; Troquier L; De Souza Silva O; Dormond O
Biochem Biophys Res Commun; 2019 Jun; 513(3):546-552. PubMed ID: 30981504
[TBL] [Abstract][Full Text] [Related]
19. Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells.
Zito CR; Jilaveanu LB; Anagnostou V; Rimm D; Bepler G; Maira SM; Hackl W; Camp R; Kluger HM; Chao HH
PLoS One; 2012; 7(2):e31331. PubMed ID: 22355357
[TBL] [Abstract][Full Text] [Related]
20. Targeting the PI3K/Akt/mTOR pathway in malignancy: rationale and clinical outlook.
Cho DC
BioDrugs; 2014 Aug; 28(4):373-81. PubMed ID: 24567265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
